Hire pharma and biotech consultants by specialty.
Project-based biotech experts and fractional leads across drug development, from the first IND to launch. Pick a specialty to see the work consultants take on, typical engagements and what to check before you hire.
- Regulatory affairs consultantsIND and NDA/BLA strategy, FDA meetings, labeling, CMC documentation.
- Contract CRAsSite monitoring, TMF review, central monitoring and site activation.
- Clinical operations consultantsStudy start-up, CRO and vendor oversight, interim clinical leadership.
- Medical writersCSRs, protocols, investigator brochures, Module 2 summaries.
- BiostatisticiansSAPs, sample size, ADaM and TLF programming, DSMB support.
- Pharmacovigilance consultantsCase processing, PSMF, aggregate reports, signal detection.
- GxP quality consultantsGCP and GMP audits, CAPA, QMS builds, inspection readiness.
- CMC consultantsProcess development, tech transfer, CDMO oversight, Module 3.
- Medical affairs consultantsMedical strategy, KOL engagement, MSL support, publications.
- Clinical data management consultantsEDC builds, data cleaning, reconciliation and database lock.
- Market access and HEOR consultantsPayer strategy, value dossiers, economic models, pricing.
Not sure which specialty you need?
Start from the deliverable.
IND-enabling work usually needs more than one person. A typical small-molecule or biologic program heading for its first IND pulls in a regulatory affairs consultant to own the strategy and the submission, a CMC consultant for Module 3 and the CDMO, and a medical writer for the protocol and investigator brochure.
Once a study is running, the pressure moves to clinical operations, contract CRAs and data management, then to biostatistics and medical writing at readout. Drug safety and GxP quality run alongside all of it.
If you are still unsure, browse the directory by keyword and read a few profiles. The work people list is often the quickest way to see who fits.
Who you usually need at each milestone
A rough guide for a small or mid-size sponsor. Most teams bring in one or two of these at a time and add the next as the program moves.
| Milestone | Specialists | What they typically deliver |
|---|---|---|
| Pre-IND meeting and first IND | Regulatory affairs, CMC, Medical writing | Regulatory strategy, the meeting package, Module 3, the protocol and investigator brochure. |
| Study start-up | Clinical operations, Contract CRAs | CRO and vendor selection, site feasibility, site activation and the trial master file. |
| Running the study | Contract CRAs, Data management, Drug safety | Monitoring visits, EDC builds and data cleaning, case processing and safety reporting. |
| Database lock and readout | Data management, Biostatistics, Medical writing | Reconciliation and lock, the statistical analysis plan, TLFs and the clinical study report. |
| Inspection readiness | GxP quality | Mock inspections, CAPA follow-through and audits of sites, vendors and CDMOs. |
| NDA or BLA | Regulatory affairs, CMC, Medical writing | Submission strategy, Module 2 summaries, Module 3 updates and responses to agency questions. |
| Launch | Medical affairs, Market access and HEOR | Medical strategy and KOL engagement, payer value dossiers and economic models. |